Therefore, the gained and lost EPIs and their corresponding DEGs, such as JRKL, RIOK1, FA2H, GPRC5A might play a critical role in the development of doxorubicin resistance in breast cancer cells and be important indicators for judging the prognosis or a therapeutic target in breast cancer patients treated with doxorubicin. Here, GPRC5A is linked to breast carcinoma.